Thursday 16 October, 2025
Objectives: The vascular system is prone to many common human diseases such as stroke, cardiac malfunction and arrest, thrombosis, hypertension…
Read moreAbstracts
Modeling PK and PK/PD in of anti-VEGF agents in a preclinical rabbit model of VEGF-induced retinal hyperpermeability
Thursday 16 October, 2025
Objectives: In animal experiments, the study design should always aim at striking a balance between providing meaningful results and limiting the…
Read morePrediction of gastric pH-mediated drug exposure changes using physiologically based pharmacokinetic modeling: A case study of itraconazole
Thursday 16 October, 2025
Objectives: Abnormal gastric acidity including achlorhydria can act as a significant source of variability in the absorption of drugs especially…
Read moreTranslational tool-based phase 2 clinical outcome predictions of the novel diarylquinoline TBAJ-587 for the treatment of tuberculosis, compared to bedaquiline and TBAJ-876
Thursday 16 October, 2025
Objectives: Bedaquiline (BDQ) is the first-in-class diarylquinoline approved for tuberculosis treatment. Notably, the BDQ-containing regimen in combination with pretomanid and…
Read moreEvaluating ceftazidime-avibactam exposure in patients undergoing automated peritoneal dialysis using population pharmacokinetic modelling
Thursday 16 October, 2025
Introduction: Ceftazidime/Avibactam (CAZ/AVI) is a recently marketed beta-lactam/beta-lactamase inhibitor antimicrobial combination treatment indicated for use in complicated intra-abdominal infections, complicated…
Read morePopulation Pharmacokinetic analysis of lopinavir in children with HIV in Africa receiving the pediatric lopinavir/ritonavir pellets formulation
Thursday 16 October, 2025
Background: Lopinavir/ritonavir (LPV/r) is widely used for the treatment of children living with HIV (CLWH) younger than 3 years of…
Read moreSimulation of Rituximab and Natalizumab biomarker efficacy using simplified QSP model of B- and T- lymphocyte dynamics in Multiple Sclerosis
Thursday 16 October, 2025
Introduction: Immune-mediated disease affecting the CNS, multiple sclerosis (MS), is the leading cause of neurological disability among people aged from…
Read moreSteps Toward Model-Informed Precision Dosing of PEG-Asparaginase in Children and Young Adults
Thursday 16 October, 2025
Introduction: Polyethylene glycol-conjugated asparaginase (PEG-ASNase) is integral in the treatment for acute lymphoblastic leukemia (ALL) in children and young adults…
Read moreModel-based prediction of optimal dosing regimen of recombinant hepatitis B human immunoglobulin
Thursday 16 October, 2025
Introduction: Hepatitis B is an infectious disease caused by hepatitis B virus (HBV) that affects the liver. 15% to 40%…
Read moreBone Remodeling QSP to Guide Clinical Trial Design of WNT pathway inhibitors
Thursday 16 October, 2025
Objectives: Targeting WNT signalling pathways has emerged as an attractive strategy to treat multiple diseases, including in oncology. WNT also plays…
Read more